Post Transplant Malignancy Changes

2007 Post Transplant Malignancy Changes for OMB Clearance
SECTION
Donor Related

FIELD

MODIFICATION/ADDITION

RATIONALE

Immunosuppression This question will be optional for adult No longer necessary.
and pediatric recipients.
Treatment

This question will be optional for adult No longer necessary.
and pediatric recipients.

Treatment outcome

This question will be optional for adult No longer necessary.
and pediatric recipients.

Post
Tx Clonality
Lymphoproliferative
Disease
and
Lymphoma

This question will be optional for adult No longer necessary.
and pediatric recipients.

Predominant cell
type

This question will be optional for adult No longer necessary.
and pediatric recipients.

Epstein-Barr virus
(EBV) status of
tumor

This question will be optional for adult No longer necessary.
and pediatric recipients.

Anatomy

This question will be optional for adult No longer necessary.
and pediatric recipients.

Lymph nodes

This question will be optional for adult No longer necessary.
and pediatric recipients.

Extranodal sites

This question will be optional for adult No longer necessary.
and pediatric recipients.

Treatment

This question will be optional for adult No longer necessary.
and pediatric recipients.

Ann Arbor Stage

This question will be optional for adult No longer necessary.
and pediatric recipients.

Treatment best
response

This question will be optional for adult No longer necessary.
and pediatric recipients.
Page 1 of 4
3/30/2007

2007 Post Transplant Malignancy Changes for OMB Clearance
SECTION
Recurrence
Pretransplant
Malignancy

FIELD

MODIFICATION/ADDITION

RATIONALE

of If skin number of
occurrences in
follow-up period

This question will be optional for adult No longer necessary.
and pediatric recipients.

If colo-rectal,
Duke’s
Classification

This question will be optional for adult No longer necessary.
and pediatric recipients.

If Lymphoma, type

This question will be optional for adult No longer necessary.
and pediatric recipients.

If Leukemia, type

This question will be optional for adult No longer necessary.
and pediatric recipients.

If other cancer,
specify

This question will be optional for adult No longer necessary.
and pediatric recipients.

Pre-existing
treatment date

This question will be optional for adult No longer necessary.
and pediatric recipients.

Pre-existing
treatment

This question will be optional for adult No longer necessary.
and pediatric recipients.

Sites affected

This question will be optional for adult No longer necessary.
and pediatric recipients.

Immunosuppression This question will be optional for adult No longer necessary.
and pediatric recipients.
Treatment of
recurrent tumor

This question will be optional for adult No longer necessary.
and pediatric recipients.

Treatment of
recurrent tumor
outcome

This question will be optional for adult No longer necessary.
and pediatric recipients.

Post Transplant De Skin, sites
Novo Solid Tumor

This question will be optional for adult No longer necessary.
and pediatric recipients.
Page 2 of 4
3/30/2007

2007 Post Transplant Malignancy Changes for OMB Clearance
SECTION

FIELD

MODIFICATION/ADDITION

RATIONALE

Skin, site location

This question will be optional for adult No longer necessary.
and pediatric recipients.

Skin, spread

This question will be optional for adult No longer necessary.
and pediatric recipients.

Skin number of
occurrences

This question will be optional for adult No longer necessary.
and pediatric recipients.

Renal carcinoma,
sites

This question will be optional for adult No longer necessary.
and pediatric recipients.

Carcinoma of the
uterus type

This question will be optional for adult No longer necessary.
and pediatric recipients.

Colo-rectal Duke’s
Classification

This question will be optional for adult No longer necessary.
and pediatric recipients.

Primary hepatic
tumor, specify type

This question will be optional for adult No longer necessary.
and pediatric recipients.

Metastatic liver
tumor, specify
original site

This question will be optional for adult No longer necessary.
and pediatric recipients.

Lung (include
bronchial)

This question will be optional for adult No longer necessary.
and pediatric recipients.

Leukemia, type

This question will be optional for adult No longer necessary.
and pediatric recipients.

Sarcomas, site

This question will be optional for adult No longer necessary.
and pediatric recipients.

Sarcomas, specify
type

This question will be optional for adult No longer necessary.
and pediatric recipients.

Other cancers,
specify type

This question will be optional for adult No longer necessary.
and pediatric recipients.
Page 3 of 4
3/30/2007

2007 Post Transplant Malignancy Changes for OMB Clearance
SECTION

FIELD

MODIFICATION/ADDITION

RATIONALE

Outcome

This question will be optional for adult No longer necessary.
and pediatric recipients.

Sites affected

This question will be optional for adult No longer necessary.
and pediatric recipients.

Immunosuppression This question will be optional for adult No longer necessary.
and pediatric recipients.
Treatment

This question will be optional for adult No longer necessary.
and pediatric recipients.

Best treatment
response

This question will be optional for adult No longer necessary.
and pediatric recipients.

Page 4 of 4
3/30/2007